FDA rejects Lilly’s sintilimab as first line treatment of NSCLC
The US Food and Drug Administration (FDA) has rejected the biologics license application (BLA) of Eli Lilly and Company (Lilly)’s sintilimab injection in nonsquamous non-small ... Read More
Lupin signs agreement for biosimilar Pegfilgrastim in Brazil
Lupin Limited has signed an exclusive distribution and marketing agreement with Biomm SA for biosimilar Pegfilgrastim in Brazil. The Indian pharma company had earlier secured ... Read More
Merck secures EC approval for Keytruda in combination therapy for lung cancer
Merck has achieved a significant milestone by obtaining approval from the European Commission (EC) for its cancer immunotherapy, Keytruda (pembrolizumab), to be used in combination ... Read More
Cantex Pharmaceuticals’ CX-01 receives FDA fast track designation in acute myeloid leukemia
Cantex Pharmaceuticals, a Florida-based biotechnology company, has achieved a significant milestone by securing Fast Track designation from the US Food and Drug Administration (FDA) for ... Read More